# Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients

> **NCT00482508** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 95 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT00482508
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2011-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00482508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00482508, "Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00482508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*